Review anchor
RAC-gamma serine/threonine-protein kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
RAC-gamma serine/threonine-protein kinase
CHEMBL4816
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats RAC-gamma serine/threonine-protein kinase as ChEMBL target CHEMBL4816, mapped to UniProt Q9Y243. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4816
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9Y243
RAC-gamma serine/threonine-protein kinase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why RAC-gamma serine/threonine-protein kinase matters
RAC-gamma serine/threonine-protein kinase is reviewed as RAC-gamma serine/threonine-protein kinase (UniProt Q9Y243); RAC-gamma serine/threonine-protein kinase shows clinical signal disease relevance led by neoplasm.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 2349 compounds, and 390 assays, with lead potency reaching pChEMBL 10.0.
Protein context
RAC-gamma serine/threonine-protein kinase
RAC-gamma serine/threonine-protein kinase Sequence length is 479 aa.
Review this target as RAC-gamma serine/threonine-protein kinase, mapped to UniProt Q9Y243. Sequence length is 479 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9Y243
Protein
Disease context
neoplasm
RAC-gamma serine/threonine-protein kinase shows clinical signal disease relevance led by neoplasm. 1 linked drug keep the rationale reviewable. Linked drugs include RUPITASERTIB.
Start review with neoplasm because it currently carries clinical signal support. Linked drugs include RUPITASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 2349 compounds, and 390 assays for this target. The dominant activity type is KI. CHEMBL5197007 is the current potency anchor at pChEMBL 10.0.
Use CHEMBL5197007 as the tractability anchor when discussing potency (pChEMBL 10.0).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 10.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why RAC-gamma serine/threonine-protein kinase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9Y243, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why neoplasm is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2349
Total Compounds
390
Total Assays
2
Approved Drugs
IC50: 489.0, KI: 802.0, EC50: 19.0, KD: 374.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5197007
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL5182446
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL5169427
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL4457064
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL4441825
|
9.9 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CAPIVASERTIB
CHEMBL2325741
|
2023 |
Source Header